Medica Central Coverage Policy

Policy Name:	**Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2)/InFUSE (Long Bones) and Allogeneic Morphogenic Protein (e.g., Osteo-AMP™) MP9763**
Effective Date:	**02/01/2026**

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica Central plans. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number. https://mo-central.medica.com/Providers/SSM-employee-health-plan-for-IL-MO-OK-providers

Medica Central coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment.

NOTE: The Health Plan is using clinical criteria developed by Carelon, a utilization management (UM) program third-party vendor, to assist in administering medical necessity criteria for recombinant human bone morphogenetic protein (rhBMP-2) used in spinal fusion. See criteria within the Carelon policy, Spine Surgery - Bone Graft Substitutes and Bone Morphogenetic Proteins.

NOTE: This policy does not address use of recombinant human bone morphogenic protein-2 (rhBMP-2)/InFUSE used in the spine

NOTE: The Health Plan is using clinical criteria developed by Carelon, a utilization management (UM) program third-party vendor, for recombinant human bone morphogenic protein-2 (rhBMP-2)/InFUSE used in the spine to assist in administering services.

Coverage Policy

Recombinant human bone morphogenic protein-2 (rhBMP-2)/InFUSE

rhBMP-2/InFUSE bone graft device systems are **COVERED** for FDA approved indications, for the treatment of:

1. Acute, open ***tibial shaft fractures*** within two weeks of the initial fracture in skeletally mature individuals and following appropriate wound management and fracture stabilization with standard fixation devices.

RhBMP-2/InFUSE bone graft device systems are considered investigative and unproven and therefore **NOT COVERED** for all other long bone indications. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the safety and efficacy or effects on health care outcomes.

Allogeneic morphogenic protein (e.g., OsteoAMP™)

Allogeneic morphogenic protein (e.g., OsteoAMP™) is considered investigative and unproven and therefore **NOT COVERED**. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the safety and efficacy or effects on health care outcomes.

- See related coverage policies: *Stem Cell Therapy for Orthopedic Applications*

Description

Osteogenic proteins (aka bone morphogenetic or morphogenic proteins; BMPs), are a family of bone-matrix polypeptides derived from a variety of mammalian species. Implantation induces a cascade of cellular events which are intended to result in formation of new bone at the treatment site. Seven BMPs have been identified with RhBMP-2/InFUSE (Medtronic, Inc.) and OsteoAMP (Bioventus, LLC) that are commercially available for use in the United States. BMP is being purported for use in treating orthopedic conditions, such as use in spinal fusion and tibial repair procedures. These products are available in various forms, including a compressible sponge, putty for mixing with bone marrow or blood, and granules for incorporation with mineralized allograft bone chips.

Recombinant Human Bone Morphogenic Protein

RhBMP-2/InFUSE bone grafting is intended to aid in the fusion of lumbar discs and in the repair of acute open tibial fractures. InFUSE is comprised of recombinant human bone morphogenic protein-2,one of the several commercially available forms..

Allogeneic Morphogenic Protein

OsteoAMP is comprised of allogeneic bone (i.e., cadaver-derived) with BMP-2, BMP-7 and other endogenous growth factors derived from the allogeneic bone marrow. These other growth factors are additional proteins with osteoinductive, angiogenic, and mitogenic properties and are bound to the bone during the harvesting process. OsteoAMP is available in various forms, including a compressible sponge, putty.

FDA Approval

Recombinant Human Bone Morphogenic Protein

InFUSE bone graft device systems (Medtronic Sofamor Danek) received initial FDA premarket approval (PMA) (P000058) in July 2002 for use in lumbar spine surgery.

InFUSE bone graft systems received initial FDA PMA approval (P000054) in April 2004 for treatment of fractures. The system was approved for treating acute, open tibial shaft fractures within two weeks of the initial fracture in skeletally mature individuals and following appropriate wound management and fracture stabilization with standard fixation devices. The original PMA has received multiple supplemental approvals.

Allogeneic Morphogenic Protein

OsteoAMP (Bioventus) is regulated by FDA's Center for Biologics Evaluation and Research as human tissue for transplantation and is supplied, stored, and distributed by licensed tissue banks that are required to register as such with FDA. Bioventus is not a registered tissue establishment and is exempt from tissue establishment licensure. Certificates, licenses, and registrations are listed on the Bioventus website.

Prior Authorization

Prior authorization is not required when using recombinant human bone morphogenic protein for all other covered indications. However, services with specific coverage criteria may be reviewed retrospectively to determine if criteria are being met. Retrospective denial may result if criteria are not met.

Coding Considerations
Use the current applicable CPT/HCPCS code(s).

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	February 21, 2024
Revised:		
Reviewed:		September 18, 2024
Retired:	Medical Policy Committee/Health Services Division	May 15, 2024
Administrative Update(s):	Reinstated effective 11/17/2024	08/28/2024

Original Effective Date:	04/01/2024
Re-Review Date(s):	09/18/2024
	09/18/2025
Administrative Update:	